J&J Risperdal Consta No Better Than Other Drugs in Study

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

March 3 (Bloomberg) -- Johnson & Johnson’s antipsychotic medicine Risperdal Consta, its third-best-selling drug, fared no better than less expensive treatments at keeping schizophrenia patients out of the hospital, U.S. researchers said. Bloomberg's Shannon Pettypiece reports. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change